{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:04:11Z","timestamp":1789527851634,"version":"build-2803163510"},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Breast cancer is a major global health concern among all malignancies, with HER2-positive breast cancer representing a particularly aggressive subtype. It affects approximately 20% of patients and is associated with a high risk of relapse. The management of HER2-positive breast cancer has been significantly improved by targeted therapies, though challenges remain, especially in resource-limited settings. Invasive fungal infections are also common and can manifest as metastatic lesions in immunocompromised cancer patients undergoing intensive treatments making the diagnosis challenging for the oncologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Description<\/jats:title>\n                    <jats:p>We report a case of a 39-year-old premenopausal female with relapsed HER2-positive breast cancer complicated by an invasive fungal infection. The patient initially presented with a 5 \u00d7 5 cm right breast lump, which was diagnosed as invasive ductal carcinoma, HER2-positive estrogen and progesterone receptor negative. Despite receiving chemotherapy with doxorubicin, cyclophosphamide, paclitaxel in the neoadjuvant setting and breast conservation surgery, the patient experienced disease recurrence. She was then treated with modified radical mastectomy followed by adjuvant chemotherapy TCH (trastuzumab, carboplatin, and docetaxel) six cycles. After three cycles, she developed high-grade fevers, renal impairment, and altered mental status. Imaging initially suggested ongoing infective vs metastatic process in bilateral renal and CNS parenchyma, so biopsy was performed from brain that revealed Aspergillus flavus infection. Treatment was adjusted to include antifungal therapy with voriconazole, and the patient\u2019s condition improved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Practical Implications<\/jats:title>\n                    <jats:p>This case underscores the critical need for biopsy of new or evolving lesions in cancer patients, particularly when imaging is not convincing enough for a relapse. Accurate diagnosis is essential to differentiate between disease progression and complications such as opportunistic infections. The occurrence of a fungal brain abscess in this patient highlights the importance of considering such invasive opportunistic infections in immunocompromised individuals, especially those undergoing intensive chemotherapy. Furthermore, the challenges faced due to the unavailability of targeted therapies in resource-limited settings emphasize the need for better access to advanced treatments and comprehensive management strategies. This case also calls for heightened vigilance and prompt diagnostic evaluation to address both cancer progression and potential opportunistic infections effectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/jcas-2025-0002","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:19:40Z","timestamp":1789525180000},"page":"8-11","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Tumor: Invasive Fungal Infection Unveiled in HER2-Positive Breast Cancer Patient Mimicking Disease Relapse"],"prefix":"10.2478","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7045-5583","authenticated-orcid":false,"given":"Maryam","family":"Imran","sequence":"first","affiliation":[{"name":"Shaukat Khanum Hospital Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Awais","family":"Majeed","sequence":"additional","affiliation":[{"name":"Shaukat Khanum Hospital Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sameen-Bin-Naeem","sequence":"additional","affiliation":[{"name":"Shaukat Khanum Hospital Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahira","family":"Yasmeen","sequence":"additional","affiliation":[{"name":"Shaukat Khanum Hospital Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Shaukat Khanum Hospital Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2026091602193879662_j_jcas-2025-0002_ref_001","doi-asserted-by":"crossref","unstructured":"Tufail M, Wu C. Cancer Statistics in Pakistan From 1994 to 2021: Data From Cancer Registry. JCO Clin Cancer Inform. 2023;7. doi:10.1200\/CCI.22.00142","DOI":"10.1200\/CCI.22.00142"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_002","doi-asserted-by":"crossref","unstructured":"Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021;41(11):1183\u20131194. doi:10.1002\/cac2.12207","DOI":"10.1002\/cac2.12207"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_003","doi-asserted-by":"crossref","unstructured":"Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?. Ann Oncol. 2013;24(2):283\u2013291. doi:10.1093\/annonc\/mds286","DOI":"10.1093\/annonc\/mds286"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_004","doi-asserted-by":"crossref","unstructured":"Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9(1):16\u201332. doi:10.1038\/nrclinonc.2011.177","DOI":"10.1038\/nrclinonc.2011.177"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_005","doi-asserted-by":"crossref","unstructured":"Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50(12):1559\u20131567. doi:10.1086\/652768","DOI":"10.1086\/652768"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_006","doi-asserted-by":"crossref","unstructured":"Slamon DJ, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med. 2011;365(14):1273\u20131283.","DOI":"10.1056\/NEJMoa0910383"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_007","doi-asserted-by":"crossref","unstructured":"O\u2019Shaughnessy J, Gradishar W, O\u2019Regan R, Gadi V. Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics. Clin Breast Cancer. 2023;23(4):350\u2013362. doi:10.1016\/j.clbc.2023.03.007","DOI":"10.1016\/j.clbc.2023.03.007"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_008","doi-asserted-by":"crossref","unstructured":"Peng L, Zhang Z, Zhao D, et al. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent\/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. Pathol Oncol Res. 2021;27:599894. doi:10.3389\/pore.2021.599894","DOI":"10.3389\/pore.2021.599894"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_009","doi-asserted-by":"crossref","unstructured":"Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J. 1988;81(9): 1109\u20131112.","DOI":"10.1097\/00007611-198809000-00011"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_010","doi-asserted-by":"crossref","unstructured":"Bai X, Luo J. Invasive Candidiasis in Patients with Solid Tumors: A Single-Center Retrospective Study. Int J Gen Med. 2023;16:2419\u20132426. doi:10.2147\/IJGM.S411","DOI":"10.2147\/IJGM.S411006"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_011","doi-asserted-by":"crossref","unstructured":"Mousset S, Buchheidt D, Heinz W, et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93(1):13\u201332. doi:10.1007\/s00277-013-1867-1","DOI":"10.1007\/s00277-013-1867-1"},{"key":"2026091602193879662_j_jcas-2025-0002_ref_012","unstructured":"Tzeng Y-L, et al. Strategies to Improve Access to Targeted Therapy in Low-Resource Settings. Global Health Action. 2019;12(1):1584520."}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/jcas-2025-0002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:19:48Z","timestamp":1789525188000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/jcas-2025-0002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/jcas-2025-0002"],"URL":"https:\/\/doi.org\/10.2478\/jcas-2025-0002","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}